BeOne Medicines (ONC)
NASDAQ:ONC
Want to see ONC full AI Analyst Report?
ONC Stock Chart & Stats
$323.87
--
Market closed
$323.87
--
Day’s Range― - ―
52-Week Range$239.25 - $385.22
Previous CloseN/A
VolumeN/A
Average Volume (3M)229.99K
Market Cap
$31.07B
Enterprise Value$34.88B
Total Cash (Recent Filing)$4.79B
Total Debt (Recent Filing)$1.15B
Price to Earnings (P/E)91.1
Beta0.77
Next Earnings
Aug 21, 2026EPS Estimate
1.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)49.88
Shares Outstanding109,720,300
10 Day Avg. Volume229,855
30 Day Avg. Volume229,992
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)7.60
Price to Sales (P/S)6.20
P/FCF Ratio35.18
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue6.08
Enterprise Value/Gross Profit6.88
Enterprise Value/Ebitda38.50
Forecast
1Y Price Target
$393.49Price Target Upside21.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)6.75
Revenue Forecast (FY)$6.48B
Bulls Say, Bears Say
Bulls Say
Turnaround To Positive Earnings & FCFBeOne has moved from multi-year losses to positive net income and free cash flow in 2025 and trailing twelve months. This durable shift improves funding for R&D and commercialization, reduces reliance on capital raises, and materially strengthens operational resilience over the next 2–6 months.
Exceptionally High Gross ProfitabilitySustained gross margins in the high-80% range provide a structural advantage: they enable rapid operating leverage as revenue scales, fund clinical programs and commercialization, and offer a margin buffer if pricing or mix pressures emerge over the medium term.
Regulatory Wins Expanding Product FootprintAccelerated FDA approval for BEQALZI establishes a commercial foothold in a hard-to-treat B‑cell indication and complements existing approvals in China. This structural regulatory progress supports durable revenue streams, enhances market positioning in hematology, and validates the company’s development strategy.
Bears Say
Recent Multi-year Cash Burn HistoryAlthough profitability returned, the company’s multi-year history of operating losses through 2024 indicates prior structural spending intensity and execution risk. That legacy raises the probability of episodic cash volatility if product launch timing or R&D outcomes deviate from plans.
Rising Total Debt In 2025Notable debt growth from 2024 to 2025 reduces financial flexibility and increases leverage exposure. If operating performance softens or confirmatory trials require additional spend, higher interest and amortization obligations could constrain reinvestment and raise refinancing risk over the medium term.
OCF Below EBITDA; Cash Volatility RiskOperating cash flow lagging EBITDA and a recent reversal from negative FCF suggest earnings include noncash items or timing effects. This weak cash conversion creates a persistent risk that free cash flow could fluctuate materially, stressing liquidity or forcing financing if growth accelerates or setbacks occur.
BeOne Medicines News
ONC FAQ
What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was $239.25 and its highest was $385.22 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $31.07B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s upcoming earnings report date is Aug 21, 2026 which is in 74 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on May 06, 2026. The company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.459 by $0.501.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate is 1.65.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,720,300 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of $1.96 in its last earnings report, beating expectations of $1.459. Following the earnings report the stock price went up 5.321%.
Which hedge fund is a major shareholder of BeOne Medicines?
Currently, no hedge funds are holding shares in ONC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$393.49 (21.50% Upside)
$393.49 (21.50% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 54.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $524.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.09%
12-Months-Change
Fundamentals
Return on Equity
12.10%
Trailing 12-Months
Asset Growth
46.43%
Trailing 12-Months
Company Description
BeOne Medicines
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
ONC Company Deck
ONC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive commercial and R&D narrative: robust revenue and margin expansion, GAAP profitability, substantial free cash flow, BRUKINSA’s clear commercial leadership backed by best‑in‑class long‑term data, multiple regulatory wins and rapid pipeline advancement. Notable risks discussed include safety/efficacy concerns with some fixed‑duration competitor regimens, competitive dynamics that require longer follow‑up, one‑time accounting/tax items and elevated operating investment for 2026. On balance the financial strength, clinical momentum and strategic pipeline depth outweigh the operational and competitive uncertainties noted.View all ONC earnings summariesONC Stock 12 Month Forecast
Average Price Target
$393.49
▲(21.50% Upside)
Technical Analysis
Ownership Overview
59.67% Insiders
11.88% Mutual Funds
21.97% Other Institutional Investors
5.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---